Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.140
+0.100 (9.62%)
At close: Jun 26, 2026, 4:00 PM EDT
1.138
-0.002 (-0.18%)
After-hours: Jun 26, 2026, 7:49 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 4.67, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 309.65% from the current stock price of 1.14.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 8, 2026.
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $6 | Buy | Reiterates | $6 | +426.32% | May 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 | Buy | Maintains | $4 | +250.88% | Apr 24, 2026 |
| BTIG | BTIG | Buy Maintains $4 | Buy | Maintains | $4 | +250.88% | Apr 7, 2026 |
Financial Forecast
Revenue This Year
206.64M
from 236.20M
Decreased by -12.51%
Revenue Next Year
159.90M
from 206.64M
Decreased by -22.62%
EPS This Year
-0.11
from -0.02
EPS Next Year
-0.19
from -0.11
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 218.6M | 184.8M | |
| Avg | 206.6M | 159.9M | |
| Low | 172.2M | 132.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -7.4% | -10.6% | |
| Avg | -12.5% | -22.6% | |
| Low | -27.1% | -35.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.11 | -0.19 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.